Alcohol - Articles - Page 3 | CARLAT PUBLISHING

A Timely Look at Community Reinforcement for Seniors With Unhealthy Alcohol Use

October 21, 2020

Jesse Koskey, MD. Dr. Koskey has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Interventions that combat isolation may be particularly important in the context of current physical distancing recommendations. This randomized trial tested whether community reinforcement paired with motivational enhancement therapy impacted outcomes among seniors with alcohol use disorder.

Efficacy and Acceptability of Varenicline for Alcohol Use Disorder

August 6, 2020

Richard Moldawsky, MD

Richard Moldawsky, MD Dr. Moldawsky has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Smoking tobacco and drinking alcohol have reciprocal influences on each other. In this meta-analysis of nine randomized studies, the authors appraise the evidence for varenicline use for alcohol use disorder specifically.

Does Baclofen Titrated to High Doses Reduce Alcohol Use?

June 10, 2020

Thomas Jordan, MD.

Thomas Jordan, MD. Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Previous trials of baclofen for alcohol use disorder have used fixed or rather low doses, and the results have been mixed. This was the first randomized trial to allow up-titration of the dose depending on the patient’s response.

Gabapentin for Alcohol Use Disorder, Redux

June 10, 2020

Rehan Aziz, MD.

Rehan Aziz, MD. Dr Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Which patients with alcohol use disorder might benefit from gabapentin most? This randomized controlled trial focused on gabapentin’s impact on alcohol use among patients with alcohol use disorder and who had also had alcohol withdrawal symptoms in the past.

Exposure Therapy Efficacious for PTSD Co-Occurring With Alcohol Use Disorder

November 22, 2019

Brian Frankel, MD

Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Prolonged exposure is one of the best treatments available for patients with PTSD. This study examines the advantages of using prolonged exposure for patients who have PTSD with co-occurring alcohol use disorder.

The COMBINE Study: A Core Paper in the Treatment of AUD

November 22, 2019

Brian Frankel, MD

Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This research update summarizes the results of the landmark COMBINE study which evaluated the effectiveness of stand-alone and combined pharmacological and behavioral interventions for treating alcohol use disorder.

Treating Alcohol Use Disorder

October 2, 2019

Albert J. Arias, MD, MS

Albert J. Arias, MD, MS
Associate Professor, Psychiatry Virginia Commonwealth University School of Medicine. Associate Division Chair, Addiction Psychiatry and Addiction Medicine. Dr. Arias has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We have five main medications to offer patients with alcohol use disorder: acamprosate, disulfiram, gabapentin, naltrexone (PO or IM), and topiramate. The combination of naltrexone and gabapentin may work better than either of these two medications alone.

Biomarkers of Alcohol Use

October 2, 2019

The newer biomarkers of alcohol use include carbohydrate-deficient transferrin; ethyl glucuronide and ethyl sulfate; and phosphatidylethanol.

Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 randomized, double-blind, placebo- controlled trial study casts doubt on using gabapentin enacarbil extended-release (GE-XR) (Horizant), an extended-release version of gabapentin, for treatment in patients with alcohol use disorder